Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Best Buy Co Inc (BBY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Best Buy Co IncTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Best Buy Co Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Best Buy Co Inc trades at $83.6 (market cap $17.55B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Best Buy Co Inc pays a 4.61% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Best Buy Co Inc nearer its low. Which is the better fit depends on your goals.

BBYXBI
Market Cap
$17.55B
Sector
Consumer CyclicalBroad Market / Factor
52-Week High
$90.17$164.28
52-Week Low
$55.52$86.92
Enterprise Value
$19.93B
Dividend Yield
4.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Best Buy Co Inc

Best Buy (BBY) trades at $82.99, up 0.68% on the day, with a neutral technical outlook despite bullish moving averages. The company shows strong profitability with 39.1% ROE and 7.88% ROA, though revenue has declined from $51.8B in 2022 to $41.5B in 2025. Recent leadership changes include a new CFO appointment and marketing chief departure, while the company tests smaller store formats to drive growth.

The stock offers modest upside to the $84.31 consensus target with solid fundamentals but faces revenue pressure and leadership transition risks. Positive cash flow trends and consistent earnings beats support the investment case, though competitive retail pressures and macroeconomic headwinds remain concerns.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.

Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.

Returns comparison

Trailing returns across standard periods

About Best Buy Co Inc

With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Read more on BBY

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI